A detailed history of Nuveen Asset Management, LLC transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 103,648 shares of TSVT stock, worth $364,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares
103,648
Previous 110,329 6.06%
Holding current value
$364,840
Previous $424,000 15.33%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.85 - $5.05 $25,721 - $33,739
-6,681 Reduced 6.06%
103,648 $489,000
Q2 2024

Aug 09, 2024

BUY
$3.6 - $5.79 $47,340 - $76,138
13,150 Added 13.53%
110,329 $424,000
Q4 2023

Feb 14, 2024

BUY
$1.57 - $4.58 $850 - $2,482
542 Added 0.56%
97,179 $414,000
Q3 2023

Nov 14, 2023

SELL
$3.14 - $11.2 $4,003 - $14,280
-1,275 Reduced 1.3%
96,637 $378,000
Q2 2023

Aug 14, 2023

BUY
$8.45 - $12.48 $196,301 - $289,922
23,231 Added 31.11%
97,912 $990,000
Q1 2023

May 15, 2023

SELL
$9.21 - $14.98 $166,065 - $270,104
-18,031 Reduced 19.45%
74,681 $761,000
Q4 2022

Feb 14, 2023

SELL
$8.57 - $17.0 $151,766 - $301,053
-17,709 Reduced 16.04%
92,712 $869,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $17.54 $24,718 - $34,518
-1,968 Reduced 1.75%
110,421 $1.61 Million
Q2 2022

Aug 15, 2022

BUY
$10.55 - $18.81 $284,881 - $507,926
27,003 Added 31.62%
112,389 $1.48 Million
Q1 2022

May 16, 2022

BUY
$11.67 - $26.72 $10,444 - $23,914
895 Added 1.06%
85,386 $1.39 Million
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $1.16 Million - $3.6 Million
84,491 New
84,491 $2.29 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $133M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.